Cara Therapeutic (NASDAQ:CARA) specializes in discovering, developing, and commercializing innovative drugs for pruritus and pain management across multiple therapeutic areas. Currently, its focus includes treating itching associated with various conditions, aiming to improve patients' quality of life through novel pharmacological approaches. Cara Therapeutic's projects involve a mix of proprietary and in-licensed compounds. With an objective to lead in the development of first-in-class medications, the company dedicates substantial efforts to clinical trials and research. Through its work, Cara Therapeutic seeks to address significant unmet medical needs, demonstrating a commitment to advancing healthcare and therapeutic outcomes for patients globally.